Ved 48 ugers behandling med Kaletra, havde 67% af patienterne plasma RNA < 50 kopier/ ml sammenlignet med 52% i nelfinavir gruppen.
Through 48 weeks of therapy, the proportion of patients in the Kaletra arm with plasma RNA < 50 copies/ ml was 67% and 52% in the nelfinavir arm.